Continued promising results from patients who have received

Continued promising results from patients who have received standard of
care treatment after vaccinations with ChronVac-C®

Of 7 patients who participated in the recently finished phase I/IIa
study with the treatment vaccine ChronVac-C® and who thereafter received
standard of care treatment for chronic hepatitis C virus infection 6
became virus free after 24 weeks of treatment. These results support the
earlier reported good results from these patients. Based on these
results ChronTech Pharma will, as has been announced previously, during
Q4 2010 apply to the Swedish Medical Product Agency for performing a
phase IIb study where patients will receive ChronVac-C® followed by
standard of care treatment and will be compared with patients who will
receive standard of care alone.

ChronTech has earlier reported that patients who participated in the
recently finished phase I/IIa study with the treatment vaccine
ChronVac-C® seem to have responded unusually well on a following
treatment with what is called standard of care, i.e. pegylated
interferon and ribavirin. Of the 7 patients who participated in the
ChronVac-C® study 5/7 (71%) had less than 50 virus copies/mL blood at
week 4, 5/7 (71%) were negative for HCV RNA at week 12, and 6/7 (85%)
were negative for HCV at week 24. The latest clinical studies have shown
that just above 50% of patients with HCV of genotype 1 are virus free
after 24 weeks with today's standard of care treatment. This indicates
that a previous treatment vaccination with ChronVac-C® gives advantages
when combined with standard of care.

 

For more information, please contact:

Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB

Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28,
E-mail: anders.vahlne@ki.se (anders.vahlne@ki.se)

 

 

About ChronTech

ChronTech develops the therapeutic DNA vaccines ChronVac-C® and
ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus
infections, i.e. chronic infections with jaundice causing viruses which
can lead to liver cirrhosis and liver cancer. ChronTech has also
developed and further develops a patent pending new type of injection
needle for a more effective uptake of DNA vaccines. ChronTech also have
part ownership in the wound healing therapy ChronSeal®, and in the new
platform technology RAS®. The ChronTech share is admitted to trade on
First North. Remium AB is Certified Adviser for ChronTech. For more
information, please visit: www.chrontech.se (http://www.chrontech.se/)

 

In the event of any discrepancy between the Swedish and English versions
of this press release, the Swedish version will take precedence.
Continued promising results from patients who have received standard of care treatment after vaccinations with ChronVac-C®

Attachments
